Improving Diabetic Wound-Healing Outcomes With Topical Growth Factor Therapies
Authors' conclusion
HUC, hEGF, and FGF are promising topical biologics with statistically significant primary outcomes compared to SOC, while PRP is effective in reducing ulcer-related AEs. HUC has been found to be the most effective in terms of cure rate and a reduction in time to cure.
Study context
- Population
- RCTs of patients with diabetic foot ulcers (DFUs); MEDLINE, EMBASE and Cochrane searched from inception to December 2022
- Comparison
- Topical biologic growth factor-containing regimens vs other biologics or standard of care (SOC)
- Outcome
- Healing rate and time to wound closure
Methodological detailsPRISMA, Jadad scale risk of bias, treatments grouped into nodes by type of biologic agent
- PRISMA
- Jadad scale risk of bias
- Treatments grouped into nodes by type of biologic agent
Pooled result
As reported in the abstract
- Human umbilical cord (HUC) was associated with the highest cure, followed by human epidermal growth factor (hEGF)
- Significantly greater reduction in time to cure DFUs with HUC, hEGF and fibroblast growth factor (FGF)
Safety
- Significantly lower risk of adverse events (AEs) with platelet-rich plasma (PRP)
Original publication
Improving Diabetic Wound-Healing Outcomes With Topical Growth Factor Therapies. J Clin Endocrinol Metab. Published 13 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →